Earnings Call · Q4 FY2021·2022-03-10

Q4 21EPS -5.88%·Rev n/aQ3 21EPS -23.08%·Rev n/aQ2 21EPS -23.53%·Rev n/aQ1 21EPS -20.00%·Rev n/a⚠ consensus missing

Decoy Therapeutics Inc. SLRX

Jason Rando — Investor Relations or Communications

David Arthur — Chief Executive Officer

Mark Rosenblum — Chief Financial Officer

−26.6%1d on move date−25.3% vs SPY3d−31.2%5d−21.8%

Research tier

Behavioral profile computed for 3 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more SLRX calls or request research access.

More SLRX calls Browse calls Request research access